|
A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC). |
|
|
Employment - Texas Oncology |
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst) |
|
|
Employment - Cullinan Oncology (I); Jounce Therapeutics (I) |
Stock and Other Ownership Interests - Jounce Therapeutics (I) |
Honoraria - Exelixis; Novartis; Pfizer |
Consulting or Advisory Role - Exelixis; Novartis; Pfizer |
Research Funding - Eisai (Inst); Exelixis (Inst); Millennium (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Lilly; Lilly; Medivation/Astellas; Nektar; Pfizer; Pharmacyclics |
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
|
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis |
|
|
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis |
Research Funding - CGI; Eisai; Novartis; Pfizer |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer |
|
|
|
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Honoraria - Boston Scientific; Medtronic |
Consulting or Advisory Role - Boston Scientific; Medtronic |
|
|
Honoraria - Alphasights (I); Dava Oncology |
Consulting or Advisory Role - Taiho Pharmaceutical (I) |
|
|
Consulting or Advisory Role - Novartis; Pfizer; Pfizer |
Speakers' Bureau - Exelixis; Ipsen; Medivation |
Research Funding - Acceleron Pharma (Inst); Alkermes (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Prometheus (Inst) |